VivoSeq
Other

Alagille Syndrome

2

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Alagille Syndrome is an early-stage landscape with 2 programs across 4 companies. The most active players are Ipsen, Mirum Pharmaceuticals, Inc., Takeda. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

1 program

Phase 3M

Mirum Pharmaceuticals, Inc.

1 program

ApprovedTakeda logo

Takeda

0 programs

PreclinicalA

Albireo, an Ipsen Company

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Odevixibat

Ipsen

Approved1

Livmarli

Mirum Pharmaceuticals, Inc.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Completed1 · 17%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Atorvastatin Therapy on Xanthoma in Alagille Syndrome
Recruiting·—·Phase 4·NCT05488067·10 enrolled
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
Recruiting·Ipsen logoIpsen·N/A·NCT06850038·30 enrolled
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Recruiting·MMirum Pharmaceuticals, Inc.·Approved·NCT07290257·230 enrolled
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)
Active, not recruiting·AAlbireo, an Ipsen Company·Phase 3·NCT05035030·62 enrolled
Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)
Not yet recruiting·Ipsen logoIpsen·N/A·NCT07585097·30 enrolled
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
Completed·Takeda logoTakeda·Phase 3·NCT05543174·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)